1 EXHIBIT 11 DURAMED PHARMACEUTICALS, INC. AND SUBSIDIARIES STATEMENT REGARDING COMPUTATION OF EARNINGS PER SHARE Three months ended March 31, 1997 1996 --------------------------------------------- Primary: Weighted average common shares outstanding 14,674,318 8,565,621 Assumed conversion of preferred shares to common shares * * Net effect of dilutive stock options and warrants - based on the treasury stock method using the average market price * * ------------- ----------- Totals 14,674,318 8,565,621 ============= =========== Net loss $( 6,758,362) $(2,436,013) ============= =========== Per share amount $ (.46) $ (.28) ============= =========== Fully diluted: Weighted average common shares outstanding 14,674,318 8,565,621 Assumed conversion of preferred shares to common shares * * Net effect of dilutive stock options - based on the treasury stock method using the year-end market price, if higher than average market price * * ------------- ----------- Totals 14,674,318 8,565,621 ============= =========== Net loss $ (6,758,362) $(2,436,013) ============= =========== Per share amount $ (.46) $ (.28) ============= =========== *Conversion of stock options and preferred shares not assumed in the computations because their effect is antidilutive. -18-